AstraZeneca in cope with Kangtai Bio to provide potential COVID-19 vaccine in China
BEIJING: AstraZeneca has signed an unique framework settlement with China’s Shenzhen Kangtai Organic Merchandise to provide its COVID-19 vaccine candidate in mainland China, the British pharmaceutical large mentioned on Thursday (Aug 6).
To satisfy market demand in China, Shenzhen Kangtai is obliged to ensure it has an annual manufacturing capability of not less than 100 million doses of the experimental shot AZD1222 – which AstraZeneca co-developed with researchers at Oxford College – by the top of this 12 months, and a capability of not less than 200 million doses by the top of subsequent 12 months, AstraZeneca mentioned in an announcement on the Chinese language social media website WeChat.
The 2 firms may even discover the possiblity of cooperation on the vaccine candidate in different markets, AstraZeneca mentioned.
Obtain our app or subscribe to our Telegram channel for the most recent updates on the coronavirus outbreak: https://cna.asia/telegram